Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: J Thorac Oncol. 2016 Jan;11(1):e5–e16. doi: 10.1016/j.jtho.2015.08.002

Table 1.

Factors associated with margin positive resection (univariate and multivariate analysis).




Categories Patients, N(col%) Margin- Positive Patients, N(row %) p-value Unadjusted OR (95% CI) p-value Adjusted OR (95% CI) p-value



Patient Characteristics N=112998 N=5335 (4.7)
Age
 18–49 6300 (5.6) 341 (5.4) <.001 1 1
 50–64 36940 (32.7) 1836 (5.0) 0.91(0.81–1.03) 0.14 1(0.88–1.13) 0.99
 65–74 42857 (37.9) 1915 (4.5) 0.82(0.73–0.92) <.001 0.84(0.72–0.99) 0.03
 75–90 26901 (23.8) 1243 (4.6) 0.85(0.75–0.96) 0.008 0.89(0.76–1.05) 0.18
Gender
 Male 54806 (48.5) 2837 (5.2) <.001 1
 Female 58192 (51.5) 2498 (4.3) 0.82(0.78–0.87) <.001 1(0.95–1.06) 0.96
Race/Ethnicity
 Non-Hispanic, White 88945 (78.7) 4111 (4.6) <.001 1 1
 Hispanic 2464 (2.2) 119 (4.8) 1.05(0.87–1.26) 0.63 0.99(0.81–1.2) 0.88
 Black 9354 (8.3) 531 (5.7) 1.24(1.13–1.36) <.001 1.15(1.04–1.27) 0.006
 Other 2931 (2.6) 131 (4.5) 0.97(0.81–1.15) 0.70 0.98(0.81–1.18) 0.80
 Missing 9304 (8.2) 443 (4.8) 1.03(0.93–1.14) 0.54 1.05(0.94–1.16) 0.41
Diagnosis Year
 2004 12859 (11.4) 606 (4.7) 0.06 1 1
 2005 13891 (12.3) 638 (4.6) 0.97(0.87–1.09) 0.64 1.02(0.9–1.14) 0.78
 2006 14216 (12.6) 662 (4.7) 0.99(0.88–1.11) 0.83 1.02(0.91–1.15) 0.73
 2007 14117 (12.5) 618 (4.4) 0.93(0.83–1.04) 0.19 0.99(0.88–1.11) 0.81
 2008 14244 (12.6) 676 (4.8) 1.01(0.9–1.13) 0.90 1.07(0.95–1.2) 0.28
 2009 14193 (12.6) 659 (4.6) 0.99(0.88–1.1) 0.79 1.04(0.93–1.17) 0.48
 2010 15114 (13.4) 791 (5.2) 1.12(1–1.25) 0.05 0.95(0.85–1.06) 0.35
 2011 14364 (12.7) 685 (4.8) 1.01(0.91–1.13) 0.83 0.89(0.79–0.99) 0.04
Insurance
 Uninsured 2185 (1.93) 133 (6.1) <.001 1.32(1.1–1.59) 0.003 1.07(0.88–1.3) 0.49
 Medicaid 4822 (4.27) 274 (5.7) 1.23(1.08–1.4) 0.002 1.03(0.9–1.18) 0.70
 Younger Medicare 6392 (5.66) 313 (4.9) 1.05(0.93–1.19) 0.43 0.99(0.87–1.13) 0.87
 Older Medicare 58853 (52.08) 2723 (4.6) 0.99(0.93–1.05) 0.73 1.16(1.04–1.3) 0.006
 Government 220 (0.19) 10 (4.6) 0.97(0.51–1.84) 0.93 0.69(0.36–1.33) 0.27
 Private 39028 (34.54) 1824 (4.8) 1 1
 Missing 1498 (1.33) 58 (3.9) 0.82(0.63–1.07) 0.15 0.86(0.65–1.13) 0.27
Median IncomeQuartile 2000
 <$30,000 14702 (13.01) 751 (5.1) <.001 1.19(1.09–1.3) <.001 1.09(0.98–1.21) 0.11
 $30,000– $34,999 20829 (18.43) 1079 (5.2) 1.21(1.12–1.31) <.001 1.14(1.04–1.24) 0.004
 $35,000– $45,999 31072 (27.5) 1498 (4.8) 1.12(1.05–1.21) 0.001 1.05(0.98–1.14) 0.18
 $46,000+ 40252 (35.62) 1736 (4.3) 1 1
 Missing 6143 (5.44) 271 (4.4) 1.02(0.9–1.17) 0.72 1.08(0.89–1.31) 0.46
Rural/Urban
 Rural 21159 (18.73) 1030 (4.9) 0.20 1.03(0.96–1.11) 0.35 0.9(0.83–0.98) 0.01
 Urban 84715 (74.97) 3995 (4.7) 1 1
 Unknown 7124 (6.3) 310 (4.4) 0.92(0.82–1.04) 0.16 0.98(0.82–1.17) 0.81
Comorbidity
 0 53437 (47.29) 2454 (4.6) 0.11 1 1
 1 40806 (36.11) 1993 (4.9) 1.07(1–1.13) 0.04 1.07(1–1.14) 0.05
 2+ 18755 (16.6) 888 (4.7) 1.03(0.95–1.12) 0.42 1.02(0.94–1.11) 0.63
Census Region
 Northeast 23892 (21.14) 946 (4.0) <.001 1 1
 Midwest 30404 (26.91) 1626 (5.4) 1.37(1.26–1.49) <.001 1.55(0.93–2.6) 0.10
 South 44324 (39.23) 2038 (4.6) 1.17(1.08–1.27) <.001 1.17(0.74–1.86) 0.51
 West 14250 (12.61) 718 (5.0) 1.29(1.17–1.42) <.001 0.98(0.48–1.97) 0.94
 Missing 128 (0.11) 7 (5.5) 1.4(0.65–3.01) 0.39 1.45(0.61–3.45) 0.41
Histology
 NOS 347 (0.31) 18 (5.2) <.001 1.37(0.85–2.2) 0.20 1.05(0.65–1.72) 0.84
 Large Cell 5320 (4.71) 261 (4.9) 1.29(1.13–1.47) <.001 0.98(0.86–1.13) 0.78
 Squamous 33768 (29.88) 2094 (6.2) 1.65(1.56–1.75) <.001 1.38(1.29–1.47) <.001
 Other 5851 (5.18) 357 (6.1) 1.62(1.45–1.82) <.001 1.34(1.19–1.51) <.001
 Adeno 67712 (59.92) 2605 (3.9) 1 1
Tumor Grade
 well/moderately differentiated 64772 (57.32) 2528 (3.9) <.001 1 1
 poorly/undifferentiated 42668 (37.76) 2557 (6.0) 1.57(1.48–1.66) <.001 1.14(1.07–1.21) <.001
 Unknown 5558 (4.92) 250 (4.5) 1.16(1.02–1.33) 0.03 0.98(0.85–1.13) 0.79
Tumor Size
 ≤3cm 68906 (60.98) 2136 (3.1) <.001 1 1
 >3cm–≤5cm 27971 (24.75) 1706 (6.1) 2.03(1.9–2.17) <.001 1.65(1.54–1.77) <.001
 >5cm 15518 (13.73) 1422 (9.2) 3.15(2.94–3.38) <.001 1.94(1.79–2.1) <.001
 Unknown 603 (0.53) 71 (11.8) 4.17(3.25–5.36) <.001 2.47(1.89–3.22) <.001
Lymph Node examined
 Yes 107002 (94.69) 4858 (4.5) <.001 1 1
 No 5888 (5.21) 467 (7.9) 1.81(1.64–2) <.001 2.14(1.9–2.41) <.001
 Unknown 108 (0.1) 10 (9.3) 2.15(1.12–4.12) 0.02 1.77(0.9–3.47) 0.10
Primary Site
 C340– Main bronchus 725 (0.64) 88 (12.1) <.001 2.79(2.22–3.49) <.001 1.4(1.1–1.78) 0.007
 C341–upper lobe 67878 (60.07) 3207 (4.7) 1 1
 C342–Middle lobe 5451 (4.82) 268 (4.9) 1.04(0.92–1.19) 0.52 1.19(1.04–1.35) 0.01
 C343–Lower lobe 35317 (31.25) 1464 (4.2) 0.87(0.82–0.93) <.001 0.83(0.78–0.89) <.001
 C348–Overlapping lesion 1883 (1.67) 182 (9.7) 2.16(1.84–2.52) 0.06 1.35(1.15–1.59) <.001
 C349–Lung NOS 1744 (1.54) 126 (7.2) 1.57(1.31–1.89) <.001 1.15(0.95–1.39) 0.16
Pathologic Stage Group
 Stage I 79614 (70.46) 1893 (2.4) <.001 1 1
 Stage II 21550 (19.07) 1950 (9.1) 4.09(3.83–4.36) <.001 3.79(3.53–4.07) <.001
 Stage III 11834 (10.47) 1492 (12.6) 5.92(5.52–6.36) <.001 5.77(5.34–6.23) <.001
TNM Path T #880
 T1 55320 (48.96) 1115 (2.0) <.001 1
 T2 48028 (42.5) 2509 (5.2) 2.68(2.49–2.88) <.001
 T3 8300 (7.35) 1516 (18.3) 10.86(10.02–11.79) <.001
 T4 667 (0.59) 146 (21.9) 13.62(11.23–16.52) <.001
 Unknown 683 (0.6) 49 (7.2) 3.76(2.79–5.06) <.001
TNM Path N #890
 N0 85272 (75.46) 2818 (3.3) <.001 1
 N1 16187 (14.33) 1342 (8.3) 2.65(2.47–2.83) <.001
 N2 9289 (8.22) 975 (10.5) 3.43(3.18–3.7) <.001
 NX 2021 (1.79) 178 (8.8) 2.83(2.41–3.31) <.001
 Unknown 229 (0.2) 22 (9.6) 3.11(2–4.83) <.001
Extent of resection
 Sublobar 15671 (13.87) 971 (6.2) <.001 1.53(1.43–1.65) <.001 1.96(1.80–2.15) <.001
 Lobe/bilobectomy 91017 (80.55) 3757 (4.1) 1 1
 Pneumonectomy 6310 (5.58) 607 (9.6) 2.47(2.26–2.71) <.001 0.98(0.89–1.09) 0.71
Facility Characteristics Facility type
 Community Cancer Program 8248 (7.3) 497 (6.0) <.001 1.62(1.42–1.84) <.001 1.34(1.12–1.61) 0.002
 Comprehensive 53784 (47.6) 2647 (4.9) <.001
 Community Cancer Program 1.31(1.18–1.44) 1.23(1.1–1.38) <.001
 Teaching/Research 27546 (24.38) 1187 (4.3) 1.14(1.02–1.26) 0.02 1.06(0.95–1.19) 0.28
 NCI Program/Network 13418 (11.87) 512 (3.8) 1 1
 7–Other 10002 (8.85) 492 (4.9) 1.3(1.15–1.48) <.001 1.23(1.07–1.4) 0.003
Proportion of Medicaid/Uninsured patients
 Q1 (low) 26715 (23.64) 1157 (4.3) 0.003 1 1
 Q2 30129 (26.66) 1433 (4.8) 1.1(1.02–1.19) 0.02 1.07(0.98–1.16) 0.13
 Q3 31222 (27.63) 1497 (4.8) 1.11(1.03–1.2) 0.008 1.08(0.99–1.18) 0.07
 Q4 (high) 24932 (22.06) 1248 (5.0) 1.16(1.07–1.26) <.001 1.13(1.03–1.24) 0.01
Lung cancer resection as proportion of all surgery
 Q1 (low) 2690 (2.38) 137 (5.1) <.001 1.13(0.95–1.35) 0.18 1.14(0.95–1.38) 0.15
 Q2 22445 (19.86) 1175 (5.2) 1.17(1.08–1.25) <.001 1.24(1.15–1.34) <.001
 Q3 38529 (34.1) 1789 (4.6) 1.03(0.96–1.09) 0.42 1.09(1.02–1.16) 0.02
 Q4 (high) 49334 (43.66) 2234 (4.5) 1 1
Total cancer surgery volume
 Q1 (low) 3377 (2.99) 206 (6.1) <.001 1.45(1.26–1.68) <.001 1.17(0.95–1.43) 0.15
 Q2 13357 (11.82) 739 (5.5) 1.31(1.21–1.42) <.001 1.17(1.05–1.3) 0.006
 Q3 26773 (23.69) 1413 (5.3) 1.25(1.17–1.33) <.001 1.19(1.1–1.28) <.001
 Q4 (high) 69491 (61.5) 2977 (4.3) 1 1
Census Division
 New England 6993 (6.19) 273 (3.9) <.001 1 1
 Middle Atlantic 17065 (15.1) 681 (4.0) 1.02(0.89–1.18) 0.75 1.03(0.89–1.19) 0.72
 East North Central 21333 (18.88) 1182 (5.5) 1.44(1.26–1.65) <.001 0.87(0.51–1.47) 0.59
 West North Central 9521 (8.43) 443 (4.7) 1.2(1.03–1.4) 0.02 0.76(0.45–1.3) 0.31
 South Atlantic 26279 (23.26) 1124 (4.3) 1.1(0.96–1.26) 0.17 0.88(0.54–1.42) 0.60
 East South Central 10175 (9) 531 (5.2) 1.36(1.17–1.57) <.001 1.03(0.63–1.67) 0.92
 West South Central 7583 (6.71) 385 (5.1) 1.32(1.12–1.54) <.001 0.98(0.6–1.6) 0.93
 Mountain 3628 (3.21) 210 (5.8) 1.51(1.26–1.82) <.001 1.41(0.69–2.9) 0.35
 Pacific 10421 (9.22) 506 (4.9) 1.26(1.08–1.46) 0.003 1.16(0.57–2.38) 0.68
Treatment Received radiation
 No 101731 (90.03) 3000 (3.0) <.001
 Yes 11267 (9.97) 2335 (20.7)
Received Chemotherapy
 No 83513 (73.91) 2638 (3.2) <.001
 Yes 29485 (26.09) 2697 (9.2)